Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: A randomized, double-blind, placebo-controlled clinical cross-over-trial

P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment

“…12,[15][16][17][18] Synthetic inhibitors of selectin also have a demonstrated ability to improve the manifestation of psoriasis and allergeninduced asthma in humans 19 and in mouse models of skin inflammation. 20 These agents are currently being tested in clinical trials for the treatment of inflammatory diseases and in preclinical studies of solid-tumor metastasis. [21][22][23][24] P-selectin glycoprotein ligand-1 (PSGL-1) is a dimeric, mucintype glycoprotein ligand that is expressed by all leukocytes and is involved in the homing of leukocytes to target tissues.…”

Eosinophil trafficking in allergy and asthma

“…In a recent randomized, double-blind, placebo-controlled clinical crossover trial, inhaled Bimosiamose effectively reduced late-phase asthmatic reactions in a series of 12 male subjects with mild allergic asthma, although the specific impact on eosinophil trafficking remains uncertain. 73 …”

Emerging drugs for asthma

“…In patients with asthma, a single intravenous dose of TBC1269 had only a minor effect on sputum eosinophils or inhaled allergen-induced late asthmatic reactions [56] . In contrast, inhaled TBC1269 significantly reduced late-phase asthmatic reactions by approximately 50% compared with placebo in mild asthmatic subjects [57] .…”